William G. Blum, MD

One star
One star
One star
One star
One half star

Rating: 4.8 out of 5 (145 ratings)

Role

Hematology Oncology
Specialty

Leukemia Myelodysplastic Syndromes
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2003

Call 404-778-0519

Background

A board certified hematologist, William G. Blum, MD, specializes in the treatment of acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia and other myeloid malignancies.

Dr. Blum is a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He serves as director of the Acute Leukemia Program at Winship Cancer Institute. He also serves on the clinical team in the Bone Marrow and Stem Cell Transplant Center at Winship.

Prior to joining Emory in 2017, Dr. Blum was professor in the Division of Hematology in the Department of Internal Medicine at The Ohio State University - James Cancer Hospital and Solove Research Institute where he mentored hematology and medical oncology fellows, and junior faculty members.

Titles & Roles

Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Director, Acute Leukemia Program

Winship Cancer Institute of Emory University

Education & Training

Education

Fellowship, Hematology & Oncology, 2003
Washington Univ School of Med
Residency, Internal Medicine, 2000
UNIVERSITY OF VIRGINIA
Medical Education, MD, 1997
Medical College of Georgia

Board Certifications

Hematology
American Board of Internal Medicine, 2004

Professional Memberships

Dr. Blum is a member of several professional organizations including American Society of Hematology, American Association of Cancer Research, American Society of Clinical Oncology, American Society of Bone Marrow Transplantation and Alliance Cooperative Group for Clinical Trials in Oncology. He is cadre member of the Alliance Leukemia Committee and principal investigator/study chair for The Leukemia & Lymphoma Society's Beat AML Master Trial. He has been an invited speaker at international meetings of the American Society of Hematology, American Society of Clinical Oncology, European Hematology Association, and the Tandem Transplant meetings of the Center for International Blood and Marrow Transplant Research/American Society of Blood and Marrow Transplantation.

Research

View Current Clinical Trials


A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias Phase I Conditions Acute Myeloid Leukemias Location Winship Cancer Institute
BAML-16-001-S12 Phase II Location Winship Cancer Institute
BAML-16-001-S17 Phase I Location Winship Cancer Institute
MRX-2843-1003 Phase I Location Winship Cancer Institute
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Phase I/II Conditions Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Location Winship Cancer Institute

Publications

Dr. Blum has authored numerous articles and abstracts in medical publications such as the Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Blood, and Leukemia.

Title/Journal	Authors	Publication Date
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial. Blood cancer journal	FW Hoff, Y Huang, RL Welkie, RT Swords, E Traer, EM Stein, TL Lin, PA Patel, RH Collins, MR Baer, VH Duong, WG Blum, ML Arellano, W Stock, O Odenike, RL Redner, T Kovacsovics, MW Deininger, JF Zeidner, RL Olin, CC Smith, JM Foran, GJ Schiller, EK Curran, KL Koenig, NA Heerema, T Chen, M Martycz, M Stefanos, SG Marcus, L Rosenberg, BJ Druker, RL Levine, A Burd, AO Yocum, UM Borate, AS Mims, JC Byrd, YF Madanat	04/03/2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies. Leukemia	N Anabtawi, D Nicolet, N Alotaibi, DR Buelow, S Orwick, T Gregory, R Raj, K Coleman, JE Kolitz, BL Powell, WG Blum, MR Baer, JC Byrd, W Stock, GL Uy, K Mrózek, AK Eisfeld, X Cheng, SD Baker, JS Blachly	03/01/2025
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. Journal of hematology & oncology	JE Cortes, GJ Roboz, MR Baer, BA Jonas, GJ Schiller, K Yee, PB Ferrell, J Yang, ES Wang, WG Blum, A Mims, H Tian, A Sheppard, S de Botton, P Montesinos, A Curti, JM Watts	01/16/2025
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood advances	FW Hoff, WG Blum, Y Huang, RL Welkie, RT Swords, E Traer, EM Stein, TL Lin, KJ Archer, PA Patel, RH Collins, MR Baer, VH Duong, ML Arellano, W Stock, O Odenike, RL Redner, T Kovacsovics, MW Deininger, JF Zeidner, RL Olin, CC Smith, JM Foran, GJ Schiller, EK Curran, KL Koenig, NA Heerema, T Chen, M Martycz, M Stefanos, SG Marcus, L Rosenberg, BJ Druker, RL Levine, A Burd, AO Yocum, UM Borate, AS Mims, JC Byrd, YF Madanat	10/22/2024
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood advances	SF Cai, Y Huang, JR Lance, HC Mao, AJ Dunbar, SN McNulty, T Druley, Y Li, MR Baer, W Stock, T Kovacsovics, WG Blum, GJ Schiller, RL Olin, JM Foran, M Litzow, T Lin, P Patel, MC Foster, M Boyiadzis, RH Collins, J Chervin, A Shoben, JA Vergilio, NA Heerema, L Rosenberg, TL Chen, AO Yocum, F Druggan, S Marcus, M Stefanos, BJ Druker, AS Mims, U Borate, A Burd, JC Byrd, RL Levine, EM Stein	01/23/2024
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia	M Ozga, D Nicolet, K Mrózek, AS Yilmaz, J Kohlschmidt, KT Larkin, JS Blachly, CC Oakes, J Buss, CJ Walker, S Orwick, V Jurinovic, M Rothenberg-Thurley, A Dufour, S Schneider, MC Sauerland, D Görlich, U Krug, WE Berdel, BJ Woermann, W Hiddemann, J Braess, M Subklewe, K Spiekermann, AJ Carroll, WG Blum, BL Powell, JE Kolitz, JO Moore, RJ Mayer, RA Larson, GL Uy, W Stock, KH Metzeler, HL Grimes, JC Byrd, N Salomonis, T Herold, AS Mims, AK Eisfeld	01/01/2024
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia. Leukemia & lymphoma	B Bhatnagar, Q Zhao, AS Mims, S Vasu, GK Behbehani, K Larkin, JS Blachly, MA Badawi, KL Hill, KR Dzwigalski, MA Phelps, W Blum, RB Klisovic, AS Ruppert, P Ranganathan, AR Walker, R Garzon	12/01/2023
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories. Blood advances	U Borate, F Yang, R Press, AS Ruppert, D Jones, S Caruthers, W Zhao, JA Vergilio, DC Pavlick, L Juckett, B Norris, T Bucy, A Burd, EM Stein, P Patel, MR Baer, W Stock, G Schiller, W Blum, T Kovacsovics, M Litzow, J Foran, NA Heerema, L Rosenberg, S Marcus, A Yocum, M Stefanos, B Druker, JC Byrd, RL Levine, A Mims	10/24/2023
Association of social deprivation with survival in younger adult patients with AML: an Alliance study. Blood advances	M Rebechi, J Kohlschmidt, K Mrózek, D Nicolet, AS Mims, JS Blachly, S Orwick, KT Larkin, CC Oakes, A Hantel, AJ Carroll, WG Blum, BL Powell, GL Uy, RM Stone, RA Larson, JC Byrd, ED Paskett, JJ Plascak, AK Eisfeld	08/08/2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer	VH Duong, AS Ruppert, AS Mims, U Borate, EM Stein, MR Baer, W Stock, T Kovacsovics, W Blum, ML Arellano, GJ Schiller, RL Olin, JM Foran, MR Litzow, TL Lin, PA Patel, MC Foster, RL Redner, Z Al-Mansour, CR Cogle, RT Swords, RH Collins, JA Vergilio, NA Heerema, L Rosenberg, AO Yocum, S Marcus, T Chen, F Druggan, M Stefanos, TJ Gana, AB Shoben, BJ Druker, A Burd, JC Byrd, RL Levine, MM Boyiadzis	08/01/2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood advances	S de Botton, P Fenaux, K Yee, C Récher, AH Wei, P Montesinos, DC Taussig, A Pigneux, T Braun, A Curti, C Grove, BA Jonas, A Khwaja, O Legrand, P Peterlin, M Arnan, W Blum, D Cilloni, DK Hiwase, JG Jurcic, J Krauter, X Thomas, JM Watts, J Yang, O Polyanskaya, J Brevard, J Sweeney, E Barrett, J Cortes	07/11/2023
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood advances	AN Saliba, SH Kaufmann, EM Stein, PA Patel, MR Baer, W Stock, M Deininger, W Blum, GJ Schiller, RL Olin, MR Litzow, TL Lin, BJ Ball, MM Boyiadzis, E Traer, O Odenike, ML Arellano, A Walker, VH Duong, T Kovacsovics, RH Collins, AB Shoben, NA Heerema, MC Foster, KL Peterson, PA Schneider, M Martycz, TJ Gana, L Rosenberg, S Marcus, AO Yocum, T Chen, M Stefanos, AS Mims, U Borate, A Burd, BJ Druker, RL Levine, JC Byrd, JM Foran	06/13/2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma. Journal for immunotherapy of cancer	S Raghunandan, M Pauly, WG Blum, M Qayed, MV Dhodapkar, M Elkhalifa, B Watkins, M Schoettler, E Horwitz, S Parikh, S Chandrakasan, K Leung, E Bryson, L Deeb, JL Kaufman, D Worthington-White, A Alazraki, JM Schecter, D Madduri, CC Jackson, E Zudaire, A Taraseviciute-Morris, A Babich, T Nesheiwat, M Vogel, N Lendvai, L Pacaud, KM Williams	05/01/2023
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia	K Mrózek, J Kohlschmidt, JS Blachly, D Nicolet, AJ Carroll, KJ Archer, AS Mims, KT Larkin, S Orwick, CC Oakes, JE Kolitz, BL Powell, WG Blum, G Marcucci, MR Baer, GL Uy, W Stock, JC Byrd, AK Eisfeld	04/01/2023
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood	N Pemmaraju, H Kantarjian, K Sweet, E Wang, J Senapati, NR Wilson, M Konopleva, AE Frankel, V Gupta, R Mesa, M Ulrickson, E Gorak, S Bhatia, T Budak-Alpdogan, J Mason, MT Garcia-Romero, N Lopez-Santiago, G Cesarman-Maus, P Vachhani, S Lee, VR Bhatt, W Blum, RB Walter, D Bixby, I Gojo, M Duvic, RK Rampal, M de Lima, J Foran, AT Fathi, AC Hall, MA Jacoby, J Lancet, G Mannis, AS Stein, A Mims, D Rizzieri, R Olin, A Perl, G Schiller, P Shami, RM Stone, S Strickland, MJ Wieduwilt, N Daver, F Ravandi, S Vasu, M Guzman, GJ Roboz, J Khoury, M Qazilbash, PP Aung, B Cuglievan, Y Madanat, MA Kharfan-Dabaja, A Pawlowska, J Taylor, M Tallman, P Dhakal, AA Lane	02/09/2023
An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia. Haematologica	W Fiedler, P Montesinos, C Schliemann, J Middeke, S Vasu, CW Scholz, J Esteve, S Mondal, B Rüter, U Burkard, A Osswald, W Blum	12/01/2022
High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. Blood advances	KT Larkin, D Nicolet, BJ Kelly, K Mrózek, S LaHaye, KE Miller, S Wijeratne, G Wheeler, J Kohlschmidt, JS Blachly, AS Mims, CJ Walker, CC Oakes, S Orwick, I Boateng, J Buss, A Heyrosa, H Desai, AJ Carroll, W Blum, BL Powell, JE Kolitz, JO Moore, RJ Mayer, RA Larson, RM Stone, ED Paskett, JC Byrd, ER Mardis, AK Eisfeld	10/11/2022
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. Haematologica	S Vasu, JK Altman, GL Uy, MS Tallman, I Gojo, G Lozanski, U Burkard, A Osswald, P James, B Rüter, W Blum	03/01/2022
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Molecular cell	D Chen, S Xia, R Zhang, Y Li, CA Famulare, H Fan, R Wu, M Wang, AC Zhu, SE Elf, R Su, L Dong, M Arellano, WG Blum, H Mao, S Lonial, W Stock, O Odenike, M Le Beau, TJ Boggon, C He, J Chen, X Gao, RL Levine, J Chen	09/16/2021
Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial. Therapeutic innovation & regulatory science	L Rosenberg, H Levaux, RL Levine, A Shah, J Denmark, N Hereema, M Owen, S Kalk, N Kenny, G Vinson, JA Vergilio, A Mims, U Borate, W Blum, E Stein, TJ Gana, M Stefanos, A Yocum, S Marcus, A Shoben, B Druker, J Byrd, A Burd	09/01/2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood advances	AR Walker, G Marcucci, J Yin, W Blum, W Stock, J Kohlschmidt, K Mrózek, AJ Carroll, AK Eisfeld, ES Wang, S Jacobson, JE Kolitz, M Thakuri, G Sutamtewagul, R Vij, RK Stuart, JC Byrd, CD Bloomfield, RM Stone, RA Larson	07/13/2021
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. American journal of hematology	C Saygin, K Larkin, JS Blachly, S Orwick, A Ngankeu, CT Gregory, MA Phelps, S Mani, A Walker, R Garzon, S Vasu, KJ Walsh, B Bhatnagar, RB Klisovic, MR Grever, G Marcucci, JC Byrd, W Blum, AS Mims	12/01/2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nature medicine	A Burd, RL Levine, AS Ruppert, AS Mims, U Borate, EM Stein, P Patel, MR Baer, W Stock, M Deininger, W Blum, G Schiller, R Olin, M Litzow, J Foran, TL Lin, B Ball, M Boyiadzis, E Traer, O Odenike, M Arellano, A Walker, VH Duong, T Kovacsovics, R Collins, AB Shoben, NA Heerema, MC Foster, JA Vergilio, T Brennan, C Vietz, E Severson, M Miller, L Rosenberg, S Marcus, A Yocum, T Chen, M Stefanos, B Druker, JC Byrd	12/01/2020
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression. Clinical cancer research : an official journal of the American Association for Cancer Research	AR Walker, JC Byrd, JS Blachly, B Bhatnagar, AS Mims, S Orwick, TL Lin, HE Crosswell, D Zhang, MD Minden, V Munugalavadla, L Long, J Liu, Y Pan, T Oellerich, H Serve, AV Rao, WG Blum	11/15/2020
Treating acute myeloid leukemia in the modern era: A primer. Cancer	WG Blum, AS Mims	11/01/2020
Phase I study of AR-42 and decitabine in acute myeloid leukemia. Leukemia & lymphoma	SG Liva, CC Coss, J Wang, W Blum, R Klisovic, B Bhatnagar, K Walsh, S Geyer, Q Zhao, R Garzon, G Marcucci, MA Phelps, AR Walker	06/01/2020
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Investigational new drugs	JY Jeon, Q Zhao, DR Buelow, M Phelps, AR Walker, AS Mims, S Vasu, G Behbehani, J Blachly, W Blum, RB Klisovic, JC Byrd, R Garzon, SD Baker, B Bhatnagar	04/01/2020
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood advances	G Marcucci, S Geyer, K Laumann, W Zhao, D Bucci, GL Uy, W Blum, AK Eisfeld, TS Pardee, ES Wang, W Stock, JE Kolitz, J Kohlschmidt, K Mrózek, CD Bloomfield, RM Stone, RA Larson	02/25/2020
Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leukemia & lymphoma	B Bhatnagar, Q Zhao, AS Mims, S Vasu, GK Behbehani, K Larkin, JS Blachly, W Blum, RB Klisovic, AS Ruppert, S Orwick, C Oakes, P Ranganathan, JC Byrd, AR Walker, R Garzon	02/01/2020
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. Leukemia	K Mrózek, AK Eisfeld, J Kohlschmidt, AJ Carroll, CJ Walker, D Nicolet, JS Blachly, M Bill, D Papaioannou, ES Wang, GL Uy, JE Kolitz, BL Powell, W Blum, RM Stone, JC Byrd, CD Bloomfield	07/01/2019
Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood advances	J Yin, B LaPlant, GL Uy, G Marcucci, W Blum, RA Larson, RM Stone, SJ Mandrekar	06/11/2019
Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease? Bone marrow transplantation	JL Vaughn, Q Zhao, N Epperla, M Puto, J Roddy, P Elder, W Blum, R Klisovic, S Jaglowski, S Penza, B William, L Andritsos, JE Brammer, C Hofmeister, Y Efebera, D Benson, S Devine, S Cataland, S Vasu	06/01/2019
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Cancer discovery	D Chen, S Xia, M Wang, R Lin, Y Li, H Mao, M Aguiar, CA Famulare, AH Shih, CW Brennan, X Gao, Y Pan, S Liu, J Fan, L Jin, L Song, A Zhou, J Mukherjee, RO Pieper, A Mishra, J Peng, M Arellano, WG Blum, S Lonial, TJ Boggon, RL Levine, J Chen	06/01/2019
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. The New England journal of medicine	N Pemmaraju, AA Lane, KL Sweet, AS Stein, S Vasu, W Blum, DA Rizzieri, ES Wang, M Duvic, JM Sloan, S Spence, S Shemesh, CL Brooks, J Balser, I Bergstein, JE Lancet, HM Kantarjian, M Konopleva	04/25/2019
Progress in the problem of relapsed or refractory acute myeloid leukemia. Current opinion in hematology	AS Mims, W Blum	03/01/2019
Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients. Bone marrow transplantation	DR Richardson, Y Huang, HL McGinty, P Elder, J Newlin, C Kirkendall, L Andritsos, D Benson, W Blum, Y Efebera, S Penza, C Hofmeister, S Jaglowski, R Klisovic, S Vasu, B William, S Devine, AE Rosko	11/01/2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica	AS Mims, A Mishra, S Orwick, J Blachly, RB Klisovic, R Garzon, AR Walker, SM Devine, KJ Walsh, S Vasu, S Whitman, G Marcucci, D Jones, NA Heerema, G Lozanski, MA Caligiuri, CD Bloomfield, JC Byrd, R Piekarz, MR Grever, W Blum	06/01/2018
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget	B Gopalakrishnan, C Cheney, R Mani, X Mo, D Bucci, A Walker, R Klisovic, B Bhatnagar, K Walsh, B Rueter, IC Waizenegger, KH Heider, W Blum, S Vasu, N Muthusamy	02/09/2018

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.8	One star One star One star One star One half star	Provider discussed treatment options
4.8	One star One star One star One star One half star	Provider included you in decisions
4.8	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	05/20/2025	Good
One star One star One star One star One star	05/17/2025	Dr. Blum is very professional, knowledgeable and friendly.
One star One star One star One star One star	05/16/2025	Dr Blum listens well, and is very good at explaining different angles of my health issues.
One star One star One star One star One star	05/15/2025	Dr Blum is always great!
One star One star One star One star One star	05/13/2025	Dr. Wm Blum is outstanding!
One star One star One star One star One star	05/10/2025	Good 100%.
One star One star One star One star One star	05/10/2025	Good
One star One star One star One star One star	04/26/2025	Dr. Blum is the most caring physician! He makes sure to include me in my treatment options and that I understand the procedures. He is also very caring and concerned that he's providing the best treatment for my illness. He is very easy to talk to and I appreciate that he includes my caregiver in everything!
One star One star One star One star One star	04/05/2025	Good
One star One star One star One star One star	03/29/2025	Dr. Blum and staff are very easy to communicate with.
One star One star One star One star One star	02/22/2025	Dr. Blum is always looking out for my best health!
One star One star One star One star One star	02/15/2025	I was so impressed with Dr. Blum. He spent so much time with me and made me feel like I was the only patient he had. He was so caring and truly wanted to make sure I understood what he was saying. I was truly amazed!
One star One star One star One star One star	02/08/2025	Dr. Blum is amazing!!! He had me explain to him what I understood about my condition (as a former educator, this is truly best practice) to ensure I actually did understand. He drew a picture of what his future expectations of the drug effects on my cancer would be, looked at and discussed pictures on my phone of side effects I have started having and created a plan and truly spent time with me and didn't make me feel like he had any other patients waiting ion him. He is brilliant but his patient Interactions and bedside manner er are second to none!!!
One star One star One star One star One star	02/04/2025	Very good doctor
One star One star One star One star One star	01/18/2025	Dr. Blum and the entire leukemia care team are amazing. The care I have received the last 6 years from the nurses on the leukemia and transplant floors to the people in the labs has been amazing. Emory saved my life.
One star One star One star One star One star	11/25/2024	Very well.
One star One star One star One star One star	11/23/2024	All my care providers worked well together as a team. I felt safe with their knowledge and skill.
One star One star One star One star One star	11/04/2024	Dr Blum and PA are the best!
One star One star One star One star One star	10/26/2024	Top notch
One star One star One star One star One star	09/01/2024	I am always very pleased to see Dr Blum
One star One star One star One star One star	08/23/2024	When I departed all my concerned had been addressed!
One star One star One star One star One star	08/10/2024	Dr Blum is excellent. I feel like he really cares.
One star One star One star One star One star	07/18/2024	Dr. William Blum is an excellent doctor.
One star One star Empty star Empty star Empty star	06/29/2024	I think Dr Blum needs empathy, diversity and cultural training. It seems he wants to speak and has little concern for what I'm requesting from or of him!
One star One star One star One star One star	06/16/2024	We feel very blessed to have Dr. Blum as our physician.